The Department of Family Medicine at Ohio State University is currently enrolling for a research study for Type 2 diabetics who are inadequately controlled on glipizide, Glimeperide, glyburide, or other sulfonylurea medication. This study evaluates the safety and effectiveness of a new diabetes drug, called dutogliptin, when taken in combination with Glimeperide, with or without Metformin, for their diabetes.
Participants will receive study related care, study medication, lab tests, glucose monitoring supplies, and nutrition and exercise counseling at no charge. The research study will last for up to 38 weeks (approximately 10 months) and there will be 8 visits to our clinic. Participants will be paid up to $900 for completing the study.
Qualified participants must be 18-85 years of age, must be currently taking a sulfonylurea (e.g., glipizide, Glimeperide, Glyburide) for Type II Diabetes, must have a screening HgA1c of 7% to 10%, must not be taking more than two diabetes medications, must have had a fasting plasma glucose result of >126 mg/dL for at least 3 months and may not be currently enrolled in a weight loss program.
If you are interested in learning more about this study, please contact Joan Allen, RN at (614) 366-6636 or by e-mail at joan.allen@osumc.edu.